Companies Krystal Biotech, Inc.
Krystal Biotech (KRYS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Krystal Biotech, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers14th pct.Of 7 peer CEOs
CEO pay, last three years
- $6,223,894FY2023
- $15,603,652FY2024
- $10,442,485FY2025
CEO total pay was $10,442,485 in fiscal 2025, down from $15,603,652 in fiscal 2024.
FY2025: salary $846,167 · bonus $682,400 · stock awards $4,104,825 · option awards $4,675,093
Executives and directors
Kathryn Romano · EVP & Chief Accounting OfficerKrish Krishnan · CEOSuma Krishnan · PresidentCatherine Mazzacco · Independent DirectorChristopher Mason · Independent DirectorDaniel S. Janney · Lead Independent DirectorDino A. Rossi · Independent DirectorE. Rand Sutherland · Independent DirectorJulian S. Gangolli · Independent DirectorKirti Ganorkar · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at Krystal Biotech, Inc. in fiscal 2025?
As disclosed, Krish Krishnan (Chairman, President, and Chief Executive Officer) was the highest-paid executive at Krystal Biotech, Inc. in fiscal 2025, with total compensation of $10,442,485.
How does Krystal Biotech, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Krish Krishnan's total compensation ranked at the 14th percentile of Krystal Biotech, Inc.'s disclosed peer group.
What is Krystal Biotech, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Krystal Biotech, Inc.'s CEO-to-median employee pay ratio was 62:1.
How did shareholders vote on Krystal Biotech, Inc.'s executive compensation?
As disclosed, 95.55% of shareholders supported Krystal Biotech, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Krystal Biotech, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Krystal Biotech, Inc. reported total board compensation of $460,500 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Krish Krishnan | $846,167 | $682,400 | $4,104,825 | $4,675,093 | $0 | $0 | $134,000 | $10,442,485 |
| Chairman, President, and Chief Executive Officer | ||||||||
| Suma Krishnan | 677,500 | 414,923 | 2,868,000 | 2,973,978 | 0 | 0 | 14,000 | 6,948,401 |
| Founder and President, R&D | ||||||||
| Kathryn Romano | 437,500 | 223,256 | 394,350 | 1,189,591 | 0 | 0 | 14,000 | 2,258,697 |
| EVP & Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Krish Krishnan | $10,442,485 | $15,603,652 | $6,223,894 | ↓ −5,161,167 |
| Suma Krishnan | 6,948,401 | 8,243,817 | 3,835,481 | ↓ −1,295,416 |
| Kathryn Romano | 2,258,697 | 3,053,517 | 2,574,971 | ↓ −794,820 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance. We strive to provide an executive compensation program that is competitive, rewards achievement of our business objectives, and aligns our executive officers interests with those of our stockholders.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Krish S. Krishnan | RSU | 2025-02-28 | — | — | 22,900 | — | $4,104,825 |
| Krish S. Krishnan | OPTION | 2025-02-28 | — | — | 39,300 | — | 4,675,093 |
| Kathryn Romano | OPTION | 2025-02-28 | — | — | 10,000 | — | 1,189,591 |
| Suma M. Krishnan | OPTION | 2025-02-28 | — | — | 25,000 | — | 2,973,978 |
| Suma M. Krishnan | RSU | 2025-02-28 | — | — | 16,000 | — | 2,868,000 |
| Kathryn Romano | RSU | 2025-02-28 | — | — | 2,200 | — | 394,350 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Krish S. Krishnan | $4,104,825 | $0 | $4,675,093 | 0.0% |
| Kathryn Romano | 394,350 | 0 | 1,189,591 | 0.0% |
| Suma M. Krishnan | 2,868,000 | 0 | 2,973,978 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kathryn Romano | RSU | 2,200 | — | $542,388 |
| Kathryn Romano | RSU | 7,500 | — | 1,849,050 |
| Kathryn Romano | Option | 10,000 | 81.91 | — |
| Kathryn Romano | Option | 10,000 | 179.25 | — |
| Krishnan | Option | 12,500 | 63.55 | — |
| Kathryn Romano | Option | 12,500 | 63.55 | — |
| Krishnan | Option | 15,000 | 81.91 | — |
| Krishnan | RSU | 16,000 | — | 3,944,640 |
| Krishnan | RSU | 22,500 | — | 5,547,150 |
| Krishnan | RSU | 22,900 | — | 5,645,766 |
| Krishnan | Option | 25,000 | 81.91 | — |
| Krishnan | Option | 25,000 | 179.25 | — |
| Krishnan | RSU | 26,250 | — | 6,471,675 |
| Krishnan | Option | 39,300 | 179.25 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel S. JanneyIndependent · Lead Independent Director · Audit · Compensation Committee (Chair) · Nominating and Corporate Governance | $115,500 | $0 | $410,972 | — | $0 | $526,472 |
| Dino A. RossiIndependent · Audit Committee (Chair) · Compensation | 81,000 | 0 | 410,972 | — | 0 | 491,972 |
| Julian S. GangolliIndependent · Audit · Compensation · Nominating and Corporate Governance Committee (Chair) | 80,500 | 0 | 410,972 | — | 0 | 491,472 |
| E. Rand SutherlandIndependent · Audit · Commercial Advisory Committee | 65,500 | 0 | 410,972 | — | 0 | 476,472 |
| Catherine MazzaccoIndependent · Nominating and Corporate Governance · Commercial Advisory Committee | 60,000 | 0 | 410,972 | — | 0 | 470,972 |
| Christopher MasonIndependent · Science and Technology Committee (Chair) | 58,000 | 0 | 410,972 | — | 0 | 468,972 |
| Suma M. KrishnanEmployee director · Science and Technology Committee | 0 | 0 | 0 | — | 0 | 0 |
| Kirti GanorkarIndependent · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Krish S. KrishnanEmployee director · Board Chair · Commercial Advisory Committee (Chair) | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $410,972 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 10,400 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $460,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $460,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Krystal Biotech as a peer
Companies that benchmark against KRYS
7 companies name KRYS as a compensation peer
- IRONWOOD PHARMACEUTICALS INCIRWDFY2024
- Merus N.V.MRUSFY2024
- Revolution Medicines, Inc.RVMDFY2025
- RHYTHM PHARMACEUTICALS, INC.RYTMFY2025
- ROCKET PHARMACEUTICALS, INC.RCKTFY2024
- TG THERAPEUTICS, INC.TGTXFY2025
- Viking Therapeutics, Inc.VKTXFY2025
Each company listed discloses KRYS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KRYS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
HALO Halozyme TherapeuticsINSM Insmed IncorporatedTGTX TG TherapeuticsVCEL Vericel CorporationAPLS Apellis PharmaceuticalsITCI Intra-Cellular TherapiesBBIO BridgeBio Pharma
Peer reciprocity
The companies Krystal Biotech, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 4 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 6 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 7 | Krystal Biotech, Inc. | 2025 | Krish Krishnan | 846,167 | 4,104,825 | 4,675,093 | 0 | 10,442,485 |
| 8 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Krystal Biotech, Inc. | 100% | not disclosed | not disclosed | Compensia, Inc. |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| TG Therapeutics | 131% | RSU 100 | No | Compensia, Inc. |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-15 | 25,679,318 | 1,195,788 | 7,008 | 95.55% | Passed |
| 2025 | 2025-05-16 | 22,543,683 | 1,423,437 | 6,146 | 94.06% | Passed |
| 2024 | 2024-05-17 | 21,697,311 | 851,690 | 7,020 | 96.22% | Passed |
| 2023 | 2023-05-19 | 18,759,786 | 907,235 | 7,389 | 95.39% | Passed |
| 2022 | 2022-05-20 | 16,441,350 | 3,335,424 | 59,920 | 83.13% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-15 | 95.55%a |
| 2025 | 2025-05-16 | 94.06%b |
| 2024 | 2024-05-17 | 96.22%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the result of the vote, although they will be considered present for the purpose of determining the presence of a quorum.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 62 : 1 |
|---|---|
| CEO total compensation | $10,442,485 |
| Median employee compensation | $168,440 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Charles Thomas | EVP, General Counsel | 2026-05-26 | D | 642 | $302 | $193,903 | Common | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 40 | 312 | 12,489 | Common | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 964 | 311 | 300,149 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 2,652 | 310 | 823,258 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 2,784 | 309 | 861,620 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 4,830 | 308 | 1,489,899 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 11,461 | 308 | 3,526,293 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 589 | 306 | 180,429 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 544 | 305 | 165,817 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 240 | 312 | 74,796 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 3,803 | 309 | 1,174,708 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 480 | 306 | 146,815 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 400 | 305 | 121,958 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 247 | 303 | 74,883 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 320 | 301 | 96,240 | Common, indirect | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 320 | 301 | 96,240 | Common, indirect | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 2,039 | 311 | 634,001 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 2,801 | 310 | 868,156 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 1,348 | 307 | 413,964 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 593 | 302 | 179,235 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 12,729 | 308 | 3,918,070 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 176 | 303 | 53,358 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 640 | 302 | 193,431 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-25 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| John Charles Thomas | EVP, General Counsel | 2026-06-25 | D | 1,000 | 347 | 347,270 | Common | Form 4 ↗ |
| John Charles Thomas | EVP, General Counsel | 2026-06-25 | A | 1,000 | 179 | 179,250 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 40 | 333 | 13,329 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 7,428 | 330 | 2,448,280 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 2,287 | 327 | 746,941 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 4,896 | 330 | 1,617,422 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 341 | 326 | 111,029 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 3,691 | 0 | 0 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 3,095 | 331 | 1,025,786 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 1,687 | 329 | 554,205 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 5,226 | 327 | 1,710,961 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 405 | 367 | 148,455 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 847 | 365 | 309,508 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,010 | 363 | 728,927 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,357 | 359 | 1,206,459 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,143 | 358 | 1,126,508 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,981 | 358 | 1,423,501 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 520 | 355 | 184,361 | Common, indirect | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 399 | 367 | 146,256 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 826 | 365 | 301,832 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,329 | 364 | 484,390 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 565 | 363 | 205,287 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,992 | 363 | 722,404 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,242 | 362 | 449,120 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,392 | 359 | 1,219,038 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,180 | 358 | 1,139,777 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,962 | 358 | 1,416,709 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,267 | 356 | 1,164,254 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 2,006 | 356 | 713,277 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 520 | 355 | 184,361 | Common, indirect | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 573 | 363 | 208,195 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,029 | 356 | 721,455 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 2,320 | 360 | 836,281 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 1,358 | 364 | 494,963 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 1,214 | 362 | 438,993 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,266 | 360 | 816,809 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,297 | 356 | 1,174,948 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-14 | — | 9,948 | — | — | 6 insiders, 12 accrual rows | ||
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 73 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Charles Thomas | EVP, General Counsel | 2026-05-26 | D | 642 | $302 | $193,903 | Common | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 40 | 312 | 12,489 | Common | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 964 | 311 | 300,149 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 2,652 | 310 | 823,258 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 2,784 | 309 | 861,620 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 4,830 | 308 | 1,489,899 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 11,461 | 308 | 3,526,293 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 589 | 306 | 180,429 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 544 | 305 | 165,817 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 240 | 312 | 74,796 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 3,803 | 309 | 1,174,708 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 480 | 306 | 146,815 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 400 | 305 | 121,958 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 247 | 303 | 74,883 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 320 | 301 | 96,240 | Common, indirect | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 320 | 301 | 96,240 | Common, indirect | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 2,039 | 311 | 634,001 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 2,801 | 310 | 868,156 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 1,348 | 307 | 413,964 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 593 | 302 | 179,235 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-06-04 | D | 12,729 | 308 | 3,918,070 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 176 | 303 | 53,358 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-06-04 | D | 640 | 302 | 193,431 | Common, open-market sale | Form 4 ↗ |
| John Charles Thomas | EVP, General Counsel | 2026-06-25 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Charles Thomas | EVP, General Counsel | 2026-06-25 | D | 1,000 | 347 | 347,270 | Common | Form 4 ↗ |
| John Charles Thomas | EVP, General Counsel | 2026-06-25 | A | 1,000 | 179 | 179,250 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 40 | 333 | 13,329 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 7,428 | 330 | 2,448,280 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 2,287 | 327 | 746,941 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 4,896 | 330 | 1,617,422 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 341 | 326 | 111,029 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 3,691 | 0 | 0 | Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 3,095 | 331 | 1,025,786 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 1,687 | 329 | 554,205 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-08-14 | D | 5,226 | 327 | 1,710,961 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 405 | 367 | 148,455 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 847 | 365 | 309,508 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,010 | 363 | 728,927 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,357 | 359 | 1,206,459 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,143 | 358 | 1,126,508 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,981 | 358 | 1,423,501 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 520 | 355 | 184,361 | Common, indirect | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 399 | 367 | 146,256 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 826 | 365 | 301,832 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,329 | 364 | 484,390 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 565 | 363 | 205,287 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,992 | 363 | 722,404 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 1,242 | 362 | 449,120 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,392 | 359 | 1,219,038 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,180 | 358 | 1,139,777 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,962 | 358 | 1,416,709 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 3,267 | 356 | 1,164,254 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 2,006 | 356 | 713,277 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 520 | 355 | 184,361 | Common, indirect | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 573 | 363 | 208,195 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,029 | 356 | 721,455 | Common, open-market sale | Form 4 ↗ |
| Suma Krishnan | Director | 2026-09-04 | D | 2,320 | 360 | 836,281 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 1,358 | 364 | 494,963 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 1,214 | 362 | 438,993 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 2,266 | 360 | 816,809 | Common, open-market sale | Form 4 ↗ |
| Krish S. Krishnan | Director | 2026-09-04 | D | 3,297 | 356 | 1,174,948 | Common, open-market sale | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dino A. Rossi | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julian S. Gangolli | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julian S. Gangolli | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Mason | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine Mazzacco | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Mason | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine Mazzacco | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| E. Rand Sutherland | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| E. Rand Sutherland | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Janney | Director | 2026-09-14 | A | 1,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Janney | Director | 2026-09-14 | A | 471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (107 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Krish Krishnan. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table” · page 45. As printed: 10,442,485. View filing ↗
- Section 01, Suma Krishnan. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table” · page 45. As printed: 6,948,401. View filing ↗
- Section 01, Kathryn Romano. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table” · page 45. As printed: 2,258,697. View filing ↗
- Section 03, Krish S. Krishnan RSU. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 03, Krish S. Krishnan OPTION. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 03, Kathryn Romano OPTION. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 03, Suma M. Krishnan OPTION. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 03, Suma M. Krishnan RSU. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 03, Kathryn Romano RSU. DEF 14A, filed 2026-04-03. Section “APPROVAL OF THE COMPENSATION POLICY.” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-03. Section “CEO Pay Ratio”. As printed: 62 : 1. View filing ↗
- Section 08, Daniel S. Janney. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 526,472. View filing ↗
- Section 08, Dino A. Rossi. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 491,972. View filing ↗
- Section 08, Julian S. Gangolli. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 491,472. View filing ↗
- Section 08, E. Rand Sutherland. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 476,472. View filing ↗
- Section 08, Catherine Mazzacco. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 470,972. View filing ↗
- Section 08, Christopher Mason. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 468,972. View filing ↗
- Section 08, Suma M. Krishnan. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kirti Ganorkar. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Krish S. Krishnan. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John Charles Thomas 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Charles Thomas 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Charles Thomas 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Charles Thomas 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-08-14. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suma Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krish S. Krishnan 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dino A. Rossi 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julian S. Gangolli 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julian S. Gangolli 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Mason 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Mazzacco 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Mason 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Mazzacco 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rand Sutherland 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rand Sutherland 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel S. Janney 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel S. Janney 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-20. Item 5.07 · say-on-pay result. As reported: 95.55% (votes for as printed: 25,679,318). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-19. Item 5.07 · say-on-pay result. As reported: 94.06% (votes for as printed: 22,543,683). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-21. Item 5.07 · say-on-pay result. As reported: 96.22% (votes for as printed: 21,697,311). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 460,500 + equity 0 + all other 0 = 460,500, summed across the director compensation table rows.
- TG Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics's own proxy. As printed: 25,571,250. View filing ↗
- Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Insmed Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. View filing ↗
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
- Krystal Biotech, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Krystal Biotech, Inc.'s own proxy. As printed: 10,442,485. View filing ↗
- Intra-Cellular Therapies, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. View filing ↗
- Section 10a, TG Therapeutics reciprocity. DEF 14A. TG Therapeutics names Krystal Biotech, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗